The stock's fall snapped a four-day winning streak.

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, ...

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster ...